UniProtKB/Swiss-Prot P37173: Variant p.Val387Met

TGF-beta receptor type-2
Gene: TGFBR2
Feedback?

Variant information Variant position:

387 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Valine (V) to Methionine (M) at position 387 (V387M, p.Val387Met). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In a breast tumor. Any additional useful information about the variant.
Other resources:

Links to websites of interest for the variant.

Variant rs35766612 [ dbSNP | Ensembl ]

Sequence information Variant position:

387 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

567 The length of the canonical sequence.
Location on the sequence:

PCGRPKMPIVHRDLKSSNIL V KNDLTCCLCDFGLSLRLDPT The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         PCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPT

Mouse                         PCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPT

Rat                           PCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPT

Chicken                       PCGRPKTPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPS

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	23 – 567	TGF-beta receptor type-2
Topological domain	188 – 567	Cytoplasmic
Domain	244 – 544	Protein kinase
Active site	379 – 379	Proton acceptor
Alternative sequence	81 – 567	Missing. In isoform 3.
Beta strand	385 – 387

Literature citations
Inhibiting mutations in the transforming growth factor beta type 2 receptor in recurrent human breast cancer.
Luecke C.D.; Philpott A.; Metcalfe J.C.; Thompson A.M.; Hughes-Davies L.; Kemp P.R.; Hesketh R.;
Cancer Res. 61:482-485(2001)
Cited for: VARIANTS BREAST TUMOR MET-387; SER-435; ALA-447 AND MET-452; CHARACTERIZATION OF VARIANTS BREAST TUMOR SER-435; ALA-447 AND MET-452; Patterns of somatic mutation in human cancer genomes.
Greenman C.; Stephens P.; Smith R.; Dalgliesh G.L.; Hunter C.; Bignell G.; Davies H.; Teague J.; Butler A.; Stevens C.; Edkins S.; O'Meara S.; Vastrik I.; Schmidt E.E.; Avis T.; Barthorpe S.; Bhamra G.; Buck G.; Choudhury B.; Clements J.; Cole J.; Dicks E.; Forbes S.; Gray K.; Halliday K.; Harrison R.; Hills K.; Hinton J.; Jenkinson A.; Jones D.; Menzies A.; Mironenko T.; Perry J.; Raine K.; Richardson D.; Shepherd R.; Small A.; Tofts C.; Varian J.; Webb T.; West S.; Widaa S.; Yates A.; Cahill D.P.; Louis D.N.; Goldstraw P.; Nicholson A.G.; Brasseur F.; Looijenga L.; Weber B.L.; Chiew Y.-E.; DeFazio A.; Greaves M.F.; Green A.R.; Campbell P.; Birney E.; Easton D.F.; Chenevix-Trench G.; Tan M.-H.; Khoo S.K.; Teh B.T.; Yuen S.T.; Leung S.Y.; Wooster R.; Futreal P.A.; Stratton M.R.;
Nature 446:153-158(2007)
Cited for: VARIANTS [LARGE SCALE ANALYSIS] ARG-61; ILE-191; MET-315; TYR-328; ILE-373; MET-387 AND SER-490;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.